Neumora Therapeutics (NMRA) Payables (2022 - 2026)

Neumora Therapeutics' Payables history runs 5 years deep, the most recent figure standing at $5.1 million for Q1 2026.

• On a quarterly basis, Payables rose 380.7% year-over-year to $5.1 million in Q1 2026; TTM through Mar 2026 was $5.1 million, a 380.7% increase from a year earlier, with the FY2025 full-year figure at $3.4 million, up 2.18% from the prior year.
• Payables climbed to $5.1 million in Q1 2026 per NMRA's latest filing, from $3.4 million in the prior quarter.
• Across five years, Payables topped out at $7.1 million in Q4 2022 and bottomed at $337000.0 in Q4 2023.
• The 5-year median for Payables is $1.9 million (2023), against an average of $2.7 million.
• Across the five-year window, Payables tumbled 95.28% in 2023 and surged 881.31% in 2024, its largest moves.
• Year by year, Payables stood at $7.1 million in 2022, then tumbled by 95.28% to $337000.0 in 2023, then jumped by 881.31% to $3.3 million in 2024, then climbed by 2.18% to $3.4 million in 2025, then surged by 49.66% to $5.1 million in 2026.
• Per Business Quant, the three latest NMRA Payables figures stand at $5.1 million (Q1 2026), $3.4 million (Q4 2025), and $549000.0 (Q3 2025).